TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03550001

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Injection CNP before NAT
Description: Injection carbon nanoparticle via rectal mucosa before neoadjuvant therapy
Study: NCT02342639

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: 550mg pills

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pill
Study: NCT03430388

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Yellow Fever vaccine (17D)
Description: Vaccination against Yellow Fever, fractional dose (0,1mL) of 17D vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Yellow Fever vaccine (17D)
Description: Vaccination against Yellow Fever, fractional dose (0,1mL) of 17D vaccine
Study: NCT02257385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UMEC/VI
Description: ELLIPTA DPI will be supplied with 30 doses (2 strips with 30 blisters per strip) where first strip contains Umeclidinium bromide (unit dose strengths 62.5 mcg per blister) blended with lactose monohydrate and magnesium stearate 0.6% weight/weight (w/w) of total drug product and second strip contains Vilanterol (unit dose strengths 25 mcg per blister) blended with lactose monohydrate and magnesium stearate 1.0% w/w of total drug product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UMEC/VI matching placebo
Description: ELLIPTA DPI will be supplied with 30 doses (2 strips with 30 blisters per strip) where first strip contains lactose monohydrate and magnesium stearate 0.6% w/w of total drug product and second strip contains lactose monohydrate and magnesium stearate 1.0% w/w of total drug product

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tiotropium
Description: Tiotropium (as bromide monohydrate) inhalation capsules 18 mcg per dose will be supplied along with HANDIHALER inhalers manufactured by Boehringer Ingelheim

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tiotropium matching placebo
Description: Tiotropium matching placebo capsules manufactured by GSK, will contain lactose and will be supplied along with HANDIHALER inhalers
Study: NCT00424840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 15 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxotere
Description: Taxotere 70 + G-CSF

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxotere
Description: Taxotere 70 + G-CSF

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxotere
Description: Taxotere 70 + G-CSF
Study: NCT03688893

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser Application for Dental Bleaching
Description: The Laser used was the Whitening Lase II (DCM EQUIPMENTS).
Study: NCT02828995

Intervention type: OTHER
Intervention: Comprehensive Diabetes Stigma Survey
Description: The surveys to be administered in the ENDSTIGMA study are as follows:~1. The Adherence to Refills and Medications for Diabetes survey is a validated, diabetes-specific survey measure utilizing patient self-report to assess diabetes medication adherence.~2. The Demographics survey will be used to assess participant baseline characteristics, including body mass index (BMI). The questions contained in this survey have been validated by Dr. Kerri Cavanaugh's research group.~3. Comprehensive Diabetes Stigma Survey is a novel survey being developed and validated in the ENDSTIGMA study. The ENDSTIGMA study will also compare the results from this survey with the medication adherence results, to determine if there is an association between diabetes stigma and medication adherence.
Study: NCT01801774

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Subtenon 20-mg triamcinolone injection
Description: Treatment arm will receive single subtenon 20-mg triamcinolone with gentamicin injection after uneventful phacoemulsification. 0.3% Tobramycin eye drop will be given to treatment arm for 28 days to blind the patient.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02749786

Intervention type: OTHER
Group type: OTHER
Intervention: Skin Biopsy
Description: Skin biopsies will be performed via the Keys punch technique from normal facial skin.
Study: NCT00744731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo for 1 week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carisbamate
Description: 400 mg/day to 1,200 mg per day
Study: NCT00509028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: Budesonide Turbuhaler 100 mcg (Pulmicort® Turbuhaler®), 100 - 400 mcg daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Asthma Therapy
Description: According to the Japanese Paediatric Guideline for the Treatment and Management of Asthma and at daily dose as judged by the investigator.
Study: NCT02034864

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment
Description: A standardized manipulative treatment according to the results of a physical examination including 7 anatomical areas will be given by trained osteopaths during 6 sessions (with an interval of 2 weeks between 2 sessions). Each session will last 45 minutes. Osteopaths will have 3 days of training in standardized manipulative treatment.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Placebo of osteopathic manipulative treatment
Description: A standardized placebo of manipulative treatment consisting in light touch and according to the results of a physical examination including 7 anatomical areas will be given by trained osteopaths during 6 sessions (with an interval of 2 weeks between 2 sessions). Each session will last 45 minutes. Osteopaths will have 3 days of training in standardized placebo of manipulative treatment.
Study: NCT04241120

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Device and app system designed for participant to self-administer Habit Reversal Training
Description: Participants will receive an awareness bracelet and an app that work together to implement key features of Habit Reversal Training. The participant will take part in psychoeducation, awareness training, and competing response training related to trichotillomania.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Reminder bracelet control condition
Description: Participants will receive a bracelet programmed to vibrate randomly several times per hour during waking hours. They will be instructed this is a reminder not to pull.
Study: NCT04459078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Intravenous administration of (200mg/3weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin Paclitacxel
Description: intravenous administration of Albumin Paclitacxel (135mg/m2, d1, d8/3w, 4-6 cycles)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Patients will be given oral of Apatinib (250mg Qd po for 5 days, take rest for 2 days every week)
Study: NCT04457661

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bacillus coagulans TCI711
Description: Using Bacillus coagulans TCI711 for one month and implementing alcohol testing at weeks 0, 1, and 4.
Study: NCT00862498

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Written Disclosure
Description: Five sessions, each spaced 1 week apart, during which participants are asked to write about their motor vehicle accident for 30 minutes. The first session of the intervention also involves a description of common reactions to a motor vehicle accident and the rationale for this treatment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Written Disclosure
Description: Five sessions, each spaced 1 week apart, during which participants are asked to write about their motor vehicle accident for 30 minutes. The first session of the intervention also involves a description of common reactions to a motor vehicle accident and the rationale for this treatment.
Study: NCT03667794

Intervention type: DIAGNOSTIC_TEST
Intervention: body plethysmography
Description: measurement of conventional lung function parameters
Study: NCT02257385

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Indacaterol
Description: Indacaterol inhalation capsules 150 mcg per dose will be supplied by GSK along with BREEZHALER inhalers manufactured by Novartis

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Indacaterol matching placebo
Description: Indacaterol matching placebo capsules manufactured by GSK, will contain lactose and will be supplied along with BREEZHALER inhalers manufactured by Novartis

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Albuterol/salbutamol Metered Dose Inhaler (MDI)
Description: Albuterol/salbutamol MDI or nebules for as needed use will be issued throughout the study. Albuterol/salbutamol will be sourced from local commercial stock. If not available locally, GSK will source centrally
Study: NCT02474459

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: iPad-Based Clinical Support Care
Description: Subjects in this treatment arm will receive deep brain stimulation (DBS) programming at regular intervals as part of routine clinical care. DBS stimulation programming will be done with the use of a iPad-based decision support system.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Clinical Care
Description: Subjects in this treatment arm will receive DBS programming at regular intervals as part of routine clinical care.
Study: NCT00413452

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: 50 mg once weekly
Study: NCT02172924

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Early Decidual stromal cell therapy
Description: Intervention given within 7 days after corticosteroids.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Late Decidual stromal cell therapy
Description: Intervention given after 7 days after corticosteroids.
Study: NCT02338141

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Portable colposcopy (Cerviscope)
Description: HPV-positive women will be evaluated with portable colposcopy (with a novel portable colposcope known as the Cerviscope) after visual inspection with acetic acid and prior to biopsy in the experimental group.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional colposcopy (Wallach Zoomscope)
Description: HPV-positive women will be evaluated with conventional colposcopy (with the Wallach Zoomscope) after visual inspection with acetic acid and prior to biopsy per usual standard of care.
Study: NCT02257385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol/salbutamol Metered Dose Inhaler (MDI)
Description: Albuterol/salbutamol MDI or nebules for as needed use will be issued throughout the study. Albuterol/salbutamol will be sourced from local commercial stock. If not available locally, GSK will source centrally
Study: NCT02123810

Intervention type: OTHER
Group type: OTHER
Intervention: CPR
Description: Simulated cardiac arrest on a manikin Chest Compression CPR for 6 minutes

Intervention type: OTHER
Group type: OTHER
Intervention: CPR
Description: Simulated cardiac arrest on a manikin Chest Compression CPR for 6 minutes
Study: NCT01284946

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exjade
Description: Orodispersible Tablet, 10 mg/Kg/day ± 5 mg/Kg/day during 24 weeks Deferasirox should be taken daily 30 minutes before breakfast
Study: NCT02550106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMALIZUMAB
Description: sub cutaneous injections of 300 mg every 4 weeks until Week 8.
Study: NCT02256852

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QBKPN SSI
Description: QBKPN SSI is administered subcutaneously for 12 weeks
Study: NCT00811369

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant + ZACTIMA
Description: ZACTIMA 100 mg tablets. Dose = 1 tablet daily until disease progression or intolerance

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fulvestrant + Placebo
Description: ZACTIMA Placebo 100 mg tablets. Dose = 1 tablet daily for duration of study.
Study: NCT01977794

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisoprolol/Amlodipine (Bisoprolol failed group)
Description: Bisoprolol/Amlodipine FDC tablet will be orally administered at an initial dose of 5 mg/5 mg once daily for 6 weeks. If blood pressure (BP) is controlled at Week 6 (Day 43), the same dose will continue for next 6 weeks. If the BP is not controlled at Day 43, the dose will be increased to Bisoprolol/Amlodipine 5mg/10mg or 10mg/5mg for next 6 weeks. Subjects who have controlled BP at Week 12 (Day 85), will continue with the same dose for next 6 weeks. If their BP is not controlled at Day 85, dose will be increased to the next level (Bisoprolol/Amlodipine 5mg/10mg for subjects receiving Bisoprolol/Amlodipine 5mg/5mg dose and Bisoprolol/Amlodipine and 10mg/10mg for subjects receiving Bisoprolol/Amlodipine 5mg/10mg dose) until Week 18 (Day 127).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisoprolol/Amlodipine (Amlodipine failed group)
Description: Bisoprolol/Amlodipine FDC tablet will be orally administered at an initial dose of 5 milligram (mg)/5 mg once daily for 6 weeks. If BP is controlled at Week 6 (Day 43), the same dose will continue for next 6 weeks. If the BP is not controlled at Day 43, the dose will be increased to Bisoprolol/Amlodipine 5mg/10mg or 10mg/5mg for next 6 weeks. Subjects who have controlled BP at Week 12 (Day 85), will continue with the same dose for next 6 weeks. If their BP is not controlled at Day 85, dose will be increased to the next level (Bisoprolol/Amlodipine 5mg/10mg for subjects receiving Bisoprolol/Amlodipine 5mg/5mg dose and Bisoprolol/Amlodipine and 10mg/10mg for subjects receiving Bisoprolol/Amlodipine 5mg/10mg dose) until Week 18 (Day 127).
Study: NCT00766337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus in combination with ranibizumab
Description: Combination therapy of 440 micrograms sirolimus injected subconjunctivally and 500 micrograms ranibizumab injected intravitreally over a 60 day treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus in combination with ranibizumab
Description: Combination therapy of 1320 micrograms sirolimus injected subconjunctivally and 500 micrograms ranibizumab injected intravitreally over a 60 day treatment period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo in combination with ranibizumab
Description: Combination therapy of placebo injected subconjunctivally and 500 micrograms ranibizumab injected intravitreally over a 60 day treatment period.
Study: NCT01101503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intensive multifactorial group
Description: Intensive multifactorial therapy and conventional multifactorial therapy will be taken for 1 year, and then take them together, and give same treatment for 10 years.~The intensive multifactorial therapy group:~1. For blood glucose control, target HbA1c \>=5.5%and \<=6.0%,fasting blood glucose \>=5.0 mmol/L and \<=6.0 mmol/L, postprandial 2 hour glucose \>= 6.0 mmol/L and \<= 7.8 mmol/L. The drugs include insulin, oral hypoglycemic agents.~2. For blood lipids control, target LDL-C \< =1.9 mmol/L, triglyceride \< =1.5 mmol/L. The drugs include statin and fibrate.~3. For blood pressure control, target \>=120/70 mmHg and \<= 130/80 mmHg. The drugs include ACE inhibitor, angiotensin II-receptor antagonist, diuretic, beta-blocker and calcium-channel blocker.~4. Others, such as aspirin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: conventional multifactorial therapy group
Description: Intensive multifactorial therapy and conventional multifactorial therapy will be taken for 1 year, and then take them together, and give same treatment for 10 years.~The conventional multifactorial therapy group:~1. For blood glucose control, target HbA1c \>6.5%and \<=7.0%,fasting blood glucose \>6.0 mmol/L and \<=7.0 mmol/L, postprandial 2 hour glucose \> 7.8 mmol/L and \<= 10.0 mmol/L. The drugs include insulin, oral hypoglycemic agents.~2. For blood lipids control, target LDL-C \> 1.9 mmol/L and \< =2.5 mmol/L, triglyceride \> 1.5 mmol/L and \< = 2.5 mmol/L. The drugs include statin and fibrate.~3. For blood pressure control, target \>130/80 mmHg and \<= 140/90 mmHg. The drugs include ACE inhibitor, angiotensin II-receptor antagonist, diuretic, beta-blocker and calcium-channel blocker.~4. Others, such as aspirin.
Study: NCT03346278

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Messaging Intervention
Description: After completing baseline procedures, study staff will activate the intervention in the participant's profile on the text messaging platform if the participant was randomized to the intervention. The text messaging platform will deliver messages by an automated algorithm. Participants will receive 4 messages per week for 6 months.
Study: NCT01101984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: diquafosol ophthalmic solution
Description: DE-089 topical ocular application, 6 times daily for 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.1% sodium hyaluronate ophthalmic solution.
Description: 0.1% HA topical ocular application, 6 times daily for 4 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.1% sodium hyaluronate ophthalmic solution.
Description: 0.1% HA topical ocular application, 6 times daily for 4 weeks.
Study: NCT01270412

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Platelet Rich Plasma (Preparation Rich in Growth Factors)
Description: intra articular injection 6ml

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma (Preparation Rich in Growth Factors)
Description: intra articular injection 6ml

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic acid
Description: Intra articular injections: 20 mg / 2 ml
Study: NCT00838396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XP19986 CR

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for XP19986 CR
Study: NCT00215332

Intervention type: DEVICE
Intervention: CHARITE
Description: Lumbar Total Disc Replacement

Intervention type: DEVICE
Intervention: CHARITE
Description: Lumbar Total Disc Replacement
Study: NCT02417831

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tamsulosin capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tamsulosin HCl
Study: NCT00501670

Intervention type: PROCEDURE
Intervention: Herpes zoster sampling procedure for VZV PCR
Description: Four types of HZ lesions will be collected (Swabs of vesicles, Swabs of papules, Swabs of crusts and Crusts), 3 replicates of each.

Intervention type: PROCEDURE
Intervention: Blood sampling
Description: Two blood samples taken, the first at the time of HZ diagnosis and the second one month later.
Study: NCT04072497

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: One shot of the zoster vaccine
Description: One shot of the zoster vaccine (with live virus \>=4.3 LgPFU per dose)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: One shot of the varicella vaccine
Description: One shot of the varicella vaccine (with live virus \>=3.3 LgPFU per dose)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: one shot of placebo
Description: one shot of placebo with no live virus
Study: NCT01246700

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sensory Attention Focused Exercise (SAFEx)
Description: Consisted of 12 weeks for SAFEx intervention, 3 times a week for an hour each session. Participants complete dynamic balance activities and a variety of seated stretches and range of motion activities. Participants are cued to focus on sensation and proprioception of limbs.~Group A received SAFEx for 12 weeks then received no treatment for 12 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sensory Attention Focused Exercise (SAFEx)
Description: Consisted of 12 weeks for SAFEx intervention, 3 times a week for an hour each session. Participants complete dynamic balance activities and a variety of seated stretches and range of motion activities. Participants are cued to focus on sensation and proprioception of limbs.~Group B received no treatment for 12 weeks, then received SAFEx for 12 weeks.
Study: NCT03304743

Intervention type: DIAGNOSTIC_TEST
Intervention: Dental panoramic radiograph
Description: If not performed within the previous 12 months at the Centre of Dentistry, an OPG will be performed during enrolment visit.~OPGs are routine low-dose x-rays that are often performed during dental check-ups, follow-ups or before dental treatments (e.g. extractions, implant placement, etc.), as they allow the evaluation of both bone and dental structures of both jaws, the sinus and temporo-mandibular joints.
Study: NCT02299830

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cryotherapy
Description: use cryotherapy to delete soft neoplasm tissue in the airway

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: argon plasma coagulation
Description: use argon plasma coagulation to delete hard neoplasm tissue in the airway

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: stent placement
Description: use stent placement to open the airway compressed by out neoplasm

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: deletion tumor tissue by snare
Description: use snare to delete polypoid neoplasm tissue in the airway
Study: NCT03364868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Insulin
Description: treatment starting at 4 months - 7 months until age 3.0 years; dose escalation scheme: daily treatment with 7.5 mg or placebo for 2 months; increasing to daily treatment with 22.5 mg or placebo for the following 2 months; increasing to daily treatment with 67.5 mg or placebo until the end of the treatment period.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: treatment starting at age 4 months - 7 months until age 3.0 years; daily treatment with insulin or placebo capsules containing filling substance (microcrystalline cellulose).
Study: NCT01304316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetracaine HCl 3% and Oxymetazoline HCl 0.05%
Description: Tetracaine HCl 3% and Oxymetazoline HCl 0.05%
Study: NCT00552721

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical therapy with strength training
Description: 12 weeks of physical therapy after Botulinum-toxin treatment (two 45-min sessions/week) with an emphasis on strength training.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical therapy without strength training
Description: 12 weeks of physical therapy after Botulinum-toxin treatment (two 45-min sessions/week) without strength training.